Investment Analysts’ Recent Ratings Updates for Rapport Therapeutics (RAPP)

A number of research firms have changed their ratings and price targets for Rapport Therapeutics (NASDAQ: RAPP):

• 5/21/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $53.00 to $65.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Rapport Therapeutics is now covered by Truist Financial Corporation. They set a “buy” rating and a $56.00 price target on the stock.
• 5/9/2026 – Rapport Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $53.00 price target on the stock.
• 4/22/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $53.00 price target on the stock.
• 4/21/2026 – Rapport Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Rapport Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $66.00 price target on the stock.
• 4/9/2026 – Rapport Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating on the stock.

Insider Buying and Selling at Rapport Therapeutics

In other news, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $40.32, for a total transaction of $17,176,521.60. Following the sale, the insider owned 6,709,228 shares of the company’s stock, valued at approximately $270,516,072.96. The trade was a 5.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Cheryl Gault sold 2,014 shares of Rapport Therapeutics stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $28.93, for a total transaction of $58,265.02. Following the sale, the chief operating officer directly owned 169,914 shares in the company, valued at $4,915,612.02. The trade was a 1.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 897,172 shares of company stock worth $35,967,206. 13.57% of the stock is currently owned by company insiders.

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.